- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | Intensity Therapeutics auf der H.C. Wainwright Konferenz: Daten, Liquidität und entscheidende Meilensteine | - | Investing.com Deutsch | ||
| 11.08. | Intensity Therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3 | 1 | Seeking Alpha | ||
| 11.08. | Intensity Therapeutics GAAP EPS of -$1.11 misses by $0.14 | 1 | Seeking Alpha | ||
| 11.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | 462 | PR Newswire | Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026
... ► Artikel lesen | |
| 11.08. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 15.07. | Intensity Therapeutics resumes patient dosing in Swiss trial | 2 | Investing.com | ||
| 15.07. | Intensity Therapeutics setzt Patientendosierung in Schweizer Studie fort | - | Investing.com Deutsch | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.07. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) | 176 | PR Newswire | First patients dosed in Switzerland
SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a... ► Artikel lesen | |
| 08.07. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.07. | Intensity Therapeutics Inc.: Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 | 191 | PR Newswire | Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer
Over 200 patients enrolled in completed INT230-6 studies... ► Artikel lesen | |
| 16.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Intensity Therapeutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 07.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 625 | PR Newswire | Cash and cash equivalents of $10.2 million as of March 31, 2026
Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC")... ► Artikel lesen | |
| 01.05. | Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 27.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 285 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| 27.03. | Intensity Therapeutics GAAP EPS of -$8.56 misses by $0.69 | 3 | Seeking Alpha | ||
| 27.03. | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 24.03. | Intensity Therapeutics erhält neues US-Patent für Krebstherapie | 3 | Investing.com Deutsch | ||
| 23.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | BioNTech SE: Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge | Gotistobart zeigte weiterhin Potenzial als chemotherapiefreie Monotherapie zur Reaktivierung der Anti-Tumor-Immunität in bereits vorbehandelten Patientinnen und Patienten mit Plattenepithelkarzinom... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| CRISPR THERAPEUTICS | 49,155 | -0,17 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,842 | +0,99 % | InflaRx NV-Aktie im Check am 19.09. (11:10 Uhr): Meine aktuelle Lageeinschätzung | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -2,78 % | Bis zu 2,1 Milliarden US-Dollar: Was die Exosomen-Deals von Eli Lilly und Takeda heute für NurExone bedeuten | ||
| IBIO | 1,109 | +1,46 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| GERON | 1,159 | +2,79 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNITYBIO | 7,380 | -0,27 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,525 | +0,40 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,368 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,073 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,842 | -0,35 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+0,97 %) liegt der Kurs bei 4,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.